Liu Jie, Huang Jian-Gang, Zeng Jin-Zhang
School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
Methods Mol Biol. 2019;2019:15-31. doi: 10.1007/978-1-4939-9585-1_2.
Retinoic acid receptors (RARs) are ligand-dependent transcription factors of nuclear hormone receptor superfamily (NR). They are important pharmacological targets and current drug development paradigms are largely based on their nuclear transcription mechanism (genomic action). However, the side effects and limited therapeutic efficacy of retinoid-like drugs with such strategy remain a problem in clinical practice. Increasing evidences have demonstrated that many NRs including RARs can act outside the nucleus in a transcription-independent manner (non-genomic action), which are often implicated in human pathological conditions, suggesting that targeting to the non-genomic signaling of NRs is an alternative method for drug discovery. We recently reported that acacetin could antagonize the non-genomic action of RARγ via tipping the balance of AKT-p53 driven by RARγ from tumor promoting to tumor suppressive effect. This chapter provides methodology for identification of acacetin as a ligand and regulator of non-genomic signaling of RARγ. These laboratory protocols should be helpful for those researchers and beginners who are passionate about identifying chemical leads to probe the non-genomic roles of RARs and other NRs for developing new therapeutic technologies.
维甲酸受体(RARs)是核激素受体超家族(NR)中依赖配体的转录因子。它们是重要的药理学靶点,当前的药物开发模式很大程度上基于其核转录机制(基因组作用)。然而,采用这种策略的类视黄醇药物的副作用和有限的治疗效果在临床实践中仍然是个问题。越来越多的证据表明,包括RARs在内的许多核受体可以以不依赖转录的方式(非基因组作用)在细胞核外发挥作用,这常常与人类病理状况有关,这表明靶向核受体的非基因组信号是药物发现的一种替代方法。我们最近报道,金合欢素可以通过使由RARγ驱动的AKT-p53平衡从促肿瘤作用转变为抑肿瘤作用,来拮抗RARγ的非基因组作用。本章提供了将金合欢素鉴定为RARγ非基因组信号的配体和调节剂的方法。这些实验方案应该会对那些热衷于鉴定化学先导物以探究RARs和其他核受体的非基因组作用以开发新治疗技术的研究人员和初学者有所帮助。